Madrigal Pharmaceuticals (MDGL)

• Market cap: $6.66B
• 1 day: -1.99%
• 5 days: -2.50%
• 1 month: -11.91%
• 3 months: 2.73%
• 6 months: 43.33%
• Year to date: -3.86%
• 1 year: 32.11%
• 5 years: 268.10%
• 10 years: 194.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

86% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 36

49% more capital invested

Capital invested by funds: $4.76B [Q3] → $7.08B (+$2.32B) [Q4]

22% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 76

11% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 10 (+1) [Q4]

10% more call options, than puts

Call options by funds: $354M | Put options by funds: $321M

10% more funds holding

Funds holding: 254 [Q3] → 280 (+26) [Q4]

1.13% more ownership

Funds ownership: 104.09% [Q3] → 105.22% (+1.13%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $405 34% upside
• Avg. target: $437 45% upside
• High target: $469 55% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup David Lebovitz 63% 1-year accuracy 10 / 16 met price target	55% upside $469	Buy Maintained	27 Feb 2025
HC Wainwright & Co. Ed Arce 33% 1-year accuracy 50 / 152 met price target	34% upside $405	Buy Maintained	27 Feb 2025